▲ Peaking
Business
Vera kidney drug Trutakna shows strong final results in Phase 3 trial
Vera Therapeutics reports strong final Phase 3 trial data for its kidney drug Trutakna, sharpening competition with Vertex.
Vertex
5 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✗
Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles
Vertex Pharma's $10 billion purchase of Crinetics sparks a near‑doubling of its shares and a biotech‑M&A surge
◼ Archived
Business
🔮 fades
Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Technology
🔮 fades
Google Vertex AI SDK Flaw Let Attackers Hijack Model Uploads via Bucket Squatting
5 news sources are covering this Technology story right now — PULSE is tracking how fast it spreads.